Atyr Pharma Inc. (NASDAQ:LIFE) has been assigned an average rating of “Hold” from the five research firms that are currently covering the company. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $6.00.
A number of analysts have recently issued reports on LIFE shares. Citigroup Inc. raised their price objective on Atyr Pharma from $3.00 to $4.00 and gave the company a “neutral” rating in a research report on Tuesday, August 16th. Zacks Investment Research raised Atyr Pharma from a “hold” rating to a “buy” rating and set a $4.00 price objective for the company in a research report on Tuesday, August 16th. Finally, JPMorgan Chase & Co. lowered their target price on Atyr Pharma from $15.00 to $10.00 and set an “overweight” rating on the stock in a research note on Thursday, August 11th.
Institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. raised its position in shares of Atyr Pharma by 220.2% in the first quarter. Goldman Sachs Group Inc. now owns 42,753 shares of the company’s stock worth $168,000 after buying an additional 29,402 shares during the period. BlackRock Fund Advisors raised its position in Atyr Pharma by 4.6% in the first quarter. BlackRock Fund Advisors now owns 464,476 shares of the company’s stock worth $1,830,000 after buying an additional 20,539 shares during the period. State Street Corp raised its position in Atyr Pharma by 51.8% in the first quarter. State Street Corp now owns 68,285 shares of the company’s stock worth $270,000 after buying an additional 23,290 shares during the period. A.R.T. Advisors LLC raised its position in Atyr Pharma by 88.8% in the second quarter. A.R.T. Advisors LLC now owns 39,143 shares of the company’s stock worth $108,000 after buying an additional 18,410 shares during the period. Finally, Bridgeway Capital Management Inc. bought a new position in Atyr Pharma during the second quarter worth approximately $133,000. Institutional investors own 44.75% of the company’s stock.
Shares of Atyr Pharma (NASDAQ:LIFE) opened at 3.30 on Friday. The firm’s market capitalization is $78.27 million. Atyr Pharma has a 12 month low of $2.48 and a 12 month high of $13.26. The firm’s 50-day moving average price is $3.18 and its 200-day moving average price is $3.44.
Atyr Pharma (NASDAQ:LIFE) last released its quarterly earnings data on Wednesday, August 10th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.71) by $0.06. On average, equities analysts anticipate that Atyr Pharma will post ($2.56) earnings per share for the current year.
Atyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings for Atyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.